From CNBC: 2024-10-29 08:24:00

Pfizer reported strong third-quarter revenue and profit, exceeding expectations due to Covid vaccine and antiviral pill Paxlovid sales. Earnings per share were $1.06 adjusted vs. 62 cents expected, with revenue hitting $17.7 billion. Pfizer is cutting costs and facing activist pressure to improve investments and performance. Paxlovid sales reached $2.7 billion, surpassing estimates. Pfizer’s non-Covid products, including cancer treatments and blood thinners, also contributed to revenue growth. Eliquis sales rose to $1.62 billion, while the RSV shot Abrysvo generated $356 million. Sales of Vyndaqel drugs for cardiomyopathy increased to $1.45 billion. Pfizer is on track to deliver $4 billion in savings by the end of the year.



Read more at CNBC: Pfizer (PFE) earnings Q3 2024